BioNTech raised to buy at Jefferies on new cancer drug
BioNTech (BNTX) stock traded higher on Tuesday after Jefferies upgraded the COVID-19 vaccine maker to Buy, citing the ...
BioNTech SE: A Strong Buy on BNT327’s Promising Cancer Treatment Prospects and Financial Fortitude
In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on BioNTech SE (BNTX – Research Report), with ...
Buy Rating Reiterated for BioNTech SE on Promising Oncology Pipeline and BNT327’s Potential
In a report released today, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on BioNTech SE (BNTX – Research Report), ...
Investing5d
Jefferies upgrades BioNTech stock on promising cancer drug potential
2 variant. Lastly, BioNTech and DualityBio were granted Fast Track designation by the FDA for their investigational drug, BNT324/DB-1311, for treating metastatic castration-resistant prostate cancer.
Investing5d
Jefferies upgrades BioNTech stock on promising cancer drug potential
Lastly, BioNTech and DualityBio were granted Fast Track designation by the FDA for their investigational drug, BNT324/DB-1311, for treating metastatic castration-resistant prostate cancer.
Hosted on MSN4d
How BioNTech, Up 26% Over Four Days, Is Riding Summit's Coattails To A Recovery
BioNTech stock has climbed 26% over four days as the German biotech rides a round of cancer treatment success from Summit ...
Forecasting The Future: 8 Analyst Projections For BioNTech
BioNTech BNTX has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from ...
Medscape6d
Nivolumab-Rucaparib Not Superior to Rucaparib as Maintenance Tx for Ovarian Cancer
The efficacy of rucaparib plus nivolumab was compared with rucaparib monotherapy as maintenance treatment for ovarian cancer.
Cancer jab shows promise in early trial results
A vaccine designed to prime the body to recognise and fight cancer cells has shown it could stimulate the immune system to ...
Investing9d
Jefferies lifts BioNTech stock price target on new drug potential
To this end, BioNTech has initiated Phase 2 global studies of BNT327 in combination with chemotherapy for breast cancer (BC) and small cell lung cancer (SCLC). Plans are also underway to finalize ...